ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

TNXP vs RLYB // FORWARD P/E MULTIPLE

Tonix Pharmaceuticals Holding Corp. (NASDAQ) VS. Rallybio Corporation (NASDAQ) • 15-METRIC TALLY: TNXP 2 — RLYB 3
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (TNXP VS. RLYB) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC TNXP RLYB SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 49.30% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% -60.00% 0.00 TIE /operating-margins <GO>
Net Profit Margin -60.00% -60.00% 0.00 TIE /net-margins <GO>
Revenue Growth (YoY) 29.80% 34.90% -5.10 RLYB /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 0.20 4.13 -3.93 RLYB /balance-sheet <GO>
Piotroski F-Score Quality 5/9 3/9 +2.00 TNXP /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 19.1 40.9 -21.80 RLYB /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple ACTIVE — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $88.3M $84.9M $3.5M TNXP /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR TNXP REV RLYB REV TNXP GROSS % RLYB GROSS % TNXP FCF RLYB FCF
FY 2025 $13.1M $858.0K 49.3% — -$103.2M -$29.8M
FY 2024 $10.1M $636.0K 23.1% — -$61.0M -$49.3M
FY 2023 $7.8M $221.0M — — -$102.0M -$60.3M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
TNXP // BETA —
RLYB // BETA —